Download PDF
Thromb Haemost 2013; 110(01): 11-13
DOI: 10.1160/TH13-06-0453
Current Controversies
Schattauer GmbH

Differences between ACC/AHA and ESC Guidelines on antiplatelet therapy in patients with acute coronary syndromes

Kurt Huber
1   3rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminenhospital, Vienna, Austria
,
Gregory Y. H. Lip
2   University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, England UK
› Author Affiliations
Further Information

Publication History

Received: 05 June 2013

Accepted: 06 June 2013

Publication Date:
30 November 2017 (online)

Also available at
    Permissions and Reprints

Referred to by:

Viewpoint: Mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromesThromb Haemost 2013; 110(07): 5-10
DOI: 10.1160/TH13-02-0142

Note: The review process for this Editorial was fully handled by Christian Weber, Editor in Chief.

 

  • References

  • 1 Hamm CW, Bassand J-P, Agewall S. et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2011; 32: 2999-3054.
    CrossrefPubMedGoogle Scholar
  • 2 Jneid H, Anderson JL, Wright RS. et al. 2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non–ST Elevation Myocardial Infarction (Updating the 2007Guideline and Replacing the 2011 Focused Update) A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012; 60: 645-681.
    CrossrefPubMedGoogle Scholar
  • 3 O’Gara PT, Kushner FG, Ascheim DD. et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial InfarctionA Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61: e78-e140.
    PubMedGoogle Scholar
  • 4 Steg PG, James SK, Atar D. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-2619.
    CrossrefPubMedGoogle Scholar
  • 5 Serebruany V, DiNicolantonio J. Mismatch Between the European and American Guidelines on Oral Antiplatelet P2Y12 Inhibitors After Acute Coronary Syndromes. Thromb Haemost 2013; 110: 5-10.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Wiviott SD, Braunwald E, McCabe CH. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
    CrossrefPubMedGoogle Scholar
  • 7 Wallentin L, Becker R, Budaj A. et al. for the PLATO Investigators Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
    CrossrefPubMedGoogle Scholar
  • 8 Patrono C, Andreotti F, Arnesen H. et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J 2011; 32: 2922-2932.
    CrossrefPubMedGoogle Scholar
  • 9 Mahaffey K W, Wojdyla DM, Carroll K. et al. PLATO Investigators. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2011; 124: 544-554.
    PubMedGoogle Scholar
  • 10 Ohman EM, Roe MT. Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Thromb Haemost 2011; 105: 763-765.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Wallentin L, Becker RC, James SK. et al. The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary.
    PubMedGoogle Scholar